Tao Chance Brown-edwards, | |
300 68th St Se, Grand Rapids, MI 49548-6927 | |
(616) 455-5000 | |
Not Available |
Full Name | Tao Chance Brown-edwards |
---|---|
Gender | Female |
Speciality | Behavior Analyst |
Location | 300 68th St Se, Grand Rapids, Michigan |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1003309519 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YP2500X | Counselor - Professional | (Michigan) | Secondary |
106S00000X | Behavior Technician | (* (Not Available)) | Secondary |
103K00000X | Behavior Analyst | (Michigan) | Primary |
Mailing Address | Practice Location Address |
---|---|
Tao Chance Brown-edwards, 7108 S Kanner Hwy, Stuart, FL 34997-7462 Ph: (855) 832-6727 | Tao Chance Brown-edwards, 300 68th St Se, Grand Rapids, MI 49548-6927 Ph: (616) 455-5000 |
News Archive
Hibiscus flower extract may have the same health benefits as red wine and tea according to new research by scientists in Taiwan. Hibiscus contains antioxidants that help control cholesterol levels and reduce heart disease, says the research in Journal of the Science of Food and Agriculture.
Calcified nodules in the retina are associated with progression to late stages of age-related macular degeneration.
A recent study reports the safety and high efficacy of an adjuvanted vaccine candidate against SARS-CoV-2 and the complications of COVID-19.
The Center for Memory & Behavioral Disorders at LifeBridge Health opens its doors on the campus of Levindale Hebrew Geriatric Center and Hospital on Tuesday, October 2 to provide comprehensive initial evaluation services to people with dementia and behavioral disorders.
Eli Lilly and Company and Transition Therapeutics Inc. has announced that the two companies have entered into a licensing and collaboration agreement granting Lilly exclusive worldwide rights to develop and commercialize Transition's gastrin based therapies, including the lead compound TT-223, which is currently in early Phase II testing.
› Verified 3 days ago